Stanford University
This will be an open-label, single group supportive care pilot study in which patients are given cannabinoid gummies in the perioperative setting to alleviate RC/UD symptoms and improve quality of life. The primary objective will be to evaluate the safety and tolerability of a cannabigerol supplement used perioperatively (from 14 days prior to surgery to 30 days following surgery) by patients undergoing radical cystectomy with urinary diversion (RC/UD).
Inclusion Criteria: 1. 18 years of age or older 2. Non-metastatic bladder cancer scheduled to undergo radical cystectomy and urinary diversion 3. Patient is able to understand consent and is willing and able to provide written informed consent 4. Patient makes their own medical decisions 5. Lives in state of California 6. Patient is able and willing to refrain from using any non-study cannabis during the screening and treatment phases of the study 7. Females of childbearing potential to utilize an acceptable birth control method while consuming the gelatin-based chewable medication 8. Be able…
Gelatin-based chewable gummies containing 25 mg of cannabigerol derived from hemp, administered for one month following a two-week lead-in dose-adjustment period.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.